An oncomir (also oncomiR) is a microRNA (miRNA) that is associated with cancer. MicroRNAs are short RNA molecules about 22 nucleotides in length. Essentially, miRNAs specifically target certain messenger RNAs (mRNAs) to prevent them from coding for a specific protein. The dysregulation of certain microRNAs (oncomirs) has been associated with specific cancer forming (oncogenic) events. Many different oncomirs have been identified in numerous types of human cancers.
Oncomirs are associated with carcinogenesis, malignant transformation, and metastasis. Some oncomir genes are oncogenes, in that overexpression of the gene leads to cancerous growth. Other oncomir genes are tumor suppressors in a normal cell, so that underexpression of the gene leads to cancerous growth.
- 1 General mechanism
- 2 History
- 3 Oncomir addiction
- 4 Potential clinical uses of miRNA
- 5 Identified oncomirs
- 6 Anti-oncomirs
- 7 See also
- 8 References
- 9 External links
Oncomirs cause cancer by down-regulating genes by both translational repression and mRNA destabilization mechanisms. These down-regulated genes may code for proteins that regulate the cell's life cycle.
Oncomirs may be at increased or decreased levels within cancerous tissue. In the case of increased oncomir activity, the oncomir is likely suppressing a tumor suppressor gene. In cases of underexpressed oncomirs, regulation is attenuated, allowing the cell to proliferate freely.
Viruses have also been found to have miRNA that mimic parts of natural regulatory human miRNA's. One example is the Epstein–Barr virus (EBV) which is associated with various types of cancer.
The first link between miRNA and the growth of cancer was reported in 2002 when researchers observed a down-regulation of miR-15a and miR-16-1 in B-cell chronic lymphocytic leukemia patients. The term is a portmanteau, derived from "oncogenic" + "miRNA", coined by Scott M. Hammond in a 2006 paper characterizing OncomiR-1.
Certain tumors may be "addicted" to oncomirs, meaning that in order to remain tumors, a constant concentration of oncomirs must be present. This is demonstrated by inactivation of the oncomir miR-21. Mice expressing miR-21 contracted pre-B malignant lymphoid-like phenotype tumors. After inactivation of miR-21, the tumors completely regressed. This addiction is part of a more general phenomenon involving oncogenes, called oncogene addiction.
Potential clinical uses of miRNA
Studies have been performed to evaluate the effectiveness of miRNAs as potential markers for cancers. MicroRNAs have shown promise in this area due to their stability and specificity to cells and tumors. A recent study investigated the use of miRNA as a biomarker in pancreatic ductal adenocarcinoma, a form of pancreatic cancer. The study analyzed RNA from biopsied pancreatic cysts to identify deviations in expression of miRNAs. The study found that 228 miRNAs were expressed differently relative to normal pancreatic cells. Included in the findings was an association between hepatocellular carcinoma and the upregulation of miR-92a, a member of OncomiR-1.
Extracellular microRNAs (exRNAs) may also be useful in clinical cancer detection. For example, in a study of cancer patients with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL), serum levels of three miRNA's, miR-21, miR-155 and miR-210, were higher in cancer patients than in healthy controls. In particular, patients with high expression of miR-21 were more apt to have a relapse-free survival. (A table listing cancer type and the associated exRNA biomarker candidates can be found in Kosaka et al..)
The OncomiR-1 line
The OncomiR-1 cluster of miRNA's is one of the best characterized set of mammalian miRNA oncogenes. The oncomir-1 gene, also known as mir-17-92, encodes a single mRNA transcript that folds into six stem loops. Several cancer-associated oncomirs are generated from these stem loops, including miR-17, miR-18, miR-19a, miR-20, miR-19b, and miR-92. It has been shown that miRNA's from the OncomiR-1 line inhibit cell death, thus increased expression of oncomir-1 leads to the development of tumors. The oncomir-1 products inhibit expression of the transcription factor E2F1, which may impact apoptosis via the ARF-p53 pathway. It is predicted that there are several hundred target mRNAs for each miRNA, and therefore likely many additional targets for the OncomiR-1 line
OncomiR Resources and Databases
There are a few online resources and databases for collecting and annotating the oncogenic and tumor-suppressive miRNAs:
OncoMir Cancer Database Online database to access TCGA miRNA sequencing based expression data from over 10,000 tumor and normal tissues. OncomiRDB: a database for the experimentally verified oncogenic and tumor-suppressive microRNAs.
miRCancer: microRNA Cancer Association Database
HMDD: Human microRNA Disease Database
PhenomiR: a knowledgebase for microRNA expression in diseases and biological processes
Oncomir A collection of microRNA expression databases
Characteristics and mechanisms of some well defined oncomirs
MicroRNA-17, or miR-17, is a member of the OncomiR-1 family and one of the first miRNA to be identified as an oncogene. miR-17 has been confirmed to target the cell cycle transcription factor E2F1, a protein that not only promotes cell growth but also death.
MicroRNA-19, or miR-19, is a member of the OncomiR-1 family, and consists of three sub classifications in both humans and mice: mir-19a, mir-19b1 and miR-19b2. miR-19 has been shown to downregulate phosphatase and tensin homolog (PTEN) effectively increasing activity of the cellular survival-promoting signal pathway PI3K-Akt.
MicroRNA-21, or miR-21, a specific oncomir, becomes more abundant in human cancer. MicroRNA-21 elevation has been found in a wide variety of cancers, including glioblastoma, breast, colorectal, lung, pancreas, skin, liver, gastric, cervical, thyroid, and various lymphatic and hematopoietic cancers. It has been found to down-regulate the tumor suppressor PDCD4, thus aiding in the cancer's invasion, intravasation and metastasis.
MicroRNA-155, or miR-155, is a commonly over-expressed oncomir in human cancers. In human breast cancer, it has been identified to target the gene which encodes for a protein called suppressor of cytokine signaling 1 (SOCS1). Recent research suggests that miR-155 negatively regulates SOCS1, but may be a feasible target in breast cancer therapy.
A strong association has been identified between miR-569 and 3q26.2, a chromosomal locus that is amplified in some breast cancers. Altered expression of the miR-569 gene has been demonstrated to affect growth and proliferation of breast epithelial cells. Ectopic expression of miR-569 resulted in tumor cell proliferation and metastasis. This occurs through miR-569 inhibition of TP53INP1, a tumor suppressor gene. In comparison to normal tissues and less malignant tumors, TP53INP1 occurs at lower levels in more invasive cancers, presumably in part due to the role played by miR-569.
List of identified oncomirs
Anti-oncomirs are a class of miRNAs that negatively regulate oncogenes. Let-7 is the first identified anti-oncomir that functions as a "post-transcriptional-gatekeeper" of certain genes that control cell growth. For example, in lung cancer some oncogenes are down-regulated by Let-7, which functions to maintain normal cell progression. Other anti-oncomirs, including miR-143 and miR-145, have been shown to down-regulate a wide range of human cancer cell lines. Tumor formation has been observed when miR-143 and miR-145 are down-regulated, particularly in colon and gastric cancer cells. When expressed in colon cancer cells, miR-143 and miR-145 are able to slow growth at the translational level by interfering with MAPK7, an enzyme responsible for cell growth. As an avenue of therapeutic research, chemical devitalization (i.e., artificial modification) of miR-143 and miR-145 may prove to be more effective version of their natural counterparts. Specifically, modified miRNAs may be imparted with increased resistance to nucleases that would otherwise break down the miRNAs.
- Hammond, SM. (Nov 2006). "RNAi, microRNAs, and human disease". Cancer Chemother Pharmacol. 58 Suppl 1: s63–8. doi:10.1007/s00280-006-0318-2. PMID 17093929.
- Medina, PP.; Nolde, M.; Slack, FJ. (Sep 2010). "OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma". Nature. 467 (7311): 86–90. Bibcode:2010Natur.467...86M. doi:10.1038/nature09284. PMID 20693987.
- Cheng, CJ.; Slack, FJ. (2012). "The duality of oncomiR addiction in the maintenance and treatment of cancer". Cancer J. 18 (3): 232–7. doi:10.1097/PPO.0b013e318258b75b. PMC 3369429. PMID 22647359.
- "Detect microRNAs most commonly found in Cancer". SBI. Retrieved 14 February 2013.
- Babu, SG.; Ponia, S.; Kumar, D. (Oct 2011). "Cellular oncomiR orthologue in EBV oncogenesis". Computers in Biology and Medicine. 41 (10): 891–898. doi:10.1016/j.compbiomed.2011.07.007. PMID 21880309.
- Calin, GA.; Dumitru, CD.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; et al. (Nov 2002). "Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia". Proc Natl Acad Sci U S A. 99 (24): 15524–9. Bibcode:2002PNAS...9915524C. doi:10.1073/pnas.242606799. PMC 137750. PMID 12434020.
- Weinstein, IB. (Jul 2002). "Cancer. Addiction to oncogenes--the Achilles heal of cancer". Science. 297 (5578): 63–4. doi:10.1126/science.1073096. PMID 12098689.
- Frampton, AE.; Gall, TM.; Castellano, L.; Stebbing, J.; Jiao, LR.; Krell, J. (Jan 2013). "Towards a clinical use of miRNAs in pancreatic cancer biopsies". Expert Rev Mol Diagn. 13 (1): 31–4. doi:10.1586/erm.12.136. PMID 23256701. Full PDF
- Lawrie, C. H.; Gal, S.; Dunlop, H. M.; Pushkaran, B.; Liggins, A. P.; Pulford, K.; Banham, A. H.; Pezzella, F.; Boultwood, J.; Wainscoat, J. S.; Hatton, C. S. R.; Harris, A. L. (2008). "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma". British Journal of Haematology. 141 (5): 672–675. doi:10.1111/j.1365-2141.2008.07077.x. PMID 18318758.
- Kosaka, N.; Iguchi, H.; Ochiya, T. (2010). "Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis". Cancer Science. 101 (10): 2087–2092. doi:10.1111/j.1349-7006.2010.01650.x. PMID 20624164.
- Hammond, SM. (Feb 2006). "MicroRNAs as oncogenes". Current Opinion in Genetics & Development. 16 (1): 4–9. doi:10.1016/j.gde.2005.12.005. PMID 16361094. Full PDF
- Krichevsky, AM.; Gabriely, G. (Jan 2009). "miR-21: a small multi-faceted RNA". J Cell Mol Med. 13 (1): 39–53. doi:10.1111/j.1582-4934.2008.00556.x. PMC 3823035. PMID 19175699.
- Asangani, IA.; Rasheed, SA.; Nikolova, DA.; Leupold, JH.; Colburn, NH.; Post, S.; Allgayer, H. (Apr 2008). "MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer". Oncogene. 27 (15): 2128–36. doi:10.1038/sj.onc.1210856. PMID 17968323.
- Jiang, S.; Zhang, HW.; Lu, MH.; He, XH.; Li, Y.; Gu, H.; Liu, MF.; Wang, ED. (Apr 2010). "MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene". Cancer Res. 70 (8): 3119–27. doi:10.1158/0008-5472.CAN-09-4250. PMID 20354188.
- Chaluvally-Raghavan, P.; Zhang, F.; Pradeep, S.; Hee-Dong, H.; Lu, Y.; Borresen-Dale, A. L.; Flores, E. R.; Sood, A. K.; Mills, G. B. (Dec 2012). "OncomiR-569 deregulate p53 pathway and initiate breast oncogenesis". Cancer Res. 72 (24, Supplement 3): P5–10–03. doi:10.1158/0008-5472.SABCS12-P5-10-03.
- Kawk, PB.; Iwasaki, S.; Tomari, Y. (Aug 2010). "The microRNA pathway and cancer". Cancer Science. 101 (11): 2309–2315. doi:10.1111/j.1349-7006.2010.01683.x. PMID 20726859. Full PDF
- Kitade, Y.; Akao, Y. (Oct 2010). "MicroRNAs and Their Therapeutic Potential for Human Diseases: MicroRNAs, miR-143 and -145, Function as Anti-oncomirs and the Application of Chemically Modified miR-143 as an Anti-cancer Drug". J Pharmacol Sci. 114 (3): 276–280. doi:10.1254/jphs.10R12FM. PMID 20953119. Full PDF